Stockscreener 앱 받기
9.37
1.74%
0.16
시장 영업 전:
9.37
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
MSN Money - MSN
Ocular Therapeutix (NASDAQ: OCUL) outlines 2026 proxy and 10M-share incentive plan increase - Stock Titan
[ARS] OCULAR THERAPEUTIX, INC SEC Filing - Stock Titan
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) - Yahoo Finance
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix (OCUL) Begins Patient Enrollment in Axpali Tr - GuruFocus
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data - Insider Monkey
Ocular Therapeutix enrolls first patient in wet AMD extension trial - Investing.com
Ocular Therapeutix enrolls first patient in wet AMD extension trial By Investing.com - Investing.com South Africa
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - GlobeNewswire
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - Sahm
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - Yahoo Finance
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Avoiding Lag: Real-Time Signals in (OCUL) Movement - Stock Traders Daily
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA FeedbackWhat's Changed - Sahm
Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates - Sahm
Ocular Therapeutix (OCUL) Quarterly Preview | Q4 2025: Profit SurprisesRevenue Diversification - Xã Thanh Hà
OCUL (Ocular Therapeutix Inc.) reports narrower Q4 2025 loss than consensus estimates, driving a 10.84 percent one-day share rally.Social Investment Platform - Cổng thông tin điện tử tỉnh Tây Ninh
OCUL (Ocular Therapeutix Inc.) tops Q4 2025 EPS estimates, shares gain slightly even as quarterly revenue declines year over year.Earnings Quality - Cổng thông tin điện tử Tỉnh Sơn La
Ocular Therapeutix™ to Host Investor Day on June 17, 2026 - ChartMill
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD - Eyes On Eyecare
Ocular Therapeutix Reports Positive Trial Data for Macular Degeneration - HarianBasis.co
Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions - Sahm
Ocular Therapeutix Hits Day High with Strong 10.84% Intraday Surge - Markets Mojo
Ocular Therapeutix Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
Ocular Therapeutix (OCUL) Stock Short Interest Analysis (Underperforming) 2026-04-20Smart Money Flow - Xã Thanh Hà
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI - Insider Monkey
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix Stock Soars to Day High with 10.45% Surge - Markets Mojo
Ocular Therapeutix (NASDAQ:OCUL) Trading 10.2% HigherHere's What Happened - MarketBeat
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Is It Time To Reconsider Ocular Therapeutix (OCUL) After Its Recent Share Price Swings? - Sahm
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data - Investing.com
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
HC Wainwright Reiterates "Buy" Rating for Ocular Therapeutix (NASDAQ:OCUL) - MarketBeat
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
3.67%
자본화:
|
볼륨(24시간):